OncoSil Medical lodges regulatory application for Macquarie Park manufacturing facility
OncoSil Medical (ASX: OSL) has submitted a regulatory application to its Notified Body to include Cyclotek’s Macquarie Park manufacturing facility in Sydney as a critical subcontractor under the Company’s existing certification. The submission, dated 2 November 2026, is described as a significant milestone towards Australian manufacturing.
The Company is targeting commercial production of the OncoSil™ device in Australia in 2H FY27, subject to regulatory approval.
The application follows Cyclotek’s achievement of ISO 13485 certification in September 2026 (company announcement of 9 September 2026). That certification confirmed Cyclotek’s Quality Management System meets the internationally recognised standard for medical device manufacturing.
Cyclotek’s ISO 13485 certification was the first gate in a multi-step regulatory pathway to local production, and the Notified Body submission now moves the Macquarie Park facility into the next stage of that sequence.
The regulatory submission is the next key step towards enabling commercial production at Macquarie Park, subject to successful completion of the Notified Body’s review and applicable approval processes.
Key points
- Regulatory application submitted to the Notified Body for the Macquarie Park facility
- Commercial production targeted for 2H FY27, subject to regulatory approval
- Cyclotek achieved ISO 13485 certification in September 2026
When big ASX news breaks, our subscribers know first
A capital-efficient manufacturing model built for scale
The Macquarie Park facility combines Cyclotek’s established infrastructure with OncoSil-owned manufacturing equipment and the Company’s proprietary manufacturing process. According to the Company, this approach enables significant manufacturing capability without the capital investment typically associated with developing a standalone production facility.
At full capacity, the manufacturing model is expected to operate with capital intensity of less than 5%.
The Company expects the facility to deliver five benefits:
- Improved gross margins
- Scalable manufacturing capacity
- Enhanced supply chain resilience
- Greater operational control
- Support for global commercial expansion
The table below sets out what each expected benefit involves, as described in the announcement.
| Expected benefit | What it means for investors |
|---|---|
| Improved gross margins | Greater production volumes and manufacturing efficiencies are expected to reduce unit manufacturing costs over time |
| Scalable manufacturing capacity | The facility is designed to accommodate increasing global demand without requiring a proportionate increase in capital investment |
| Enhanced supply chain resilience | Australian manufacturing capability is expected to strengthen the reliability and flexibility of global product supply |
| Greater operational control | The model is expected to provide improved oversight of product quality, manufacturing processes and production planning |
| Support for global commercial expansion | Increased production capability will provide a foundation for broader adoption of the device across approved markets |
Why gross margins matter
Greater production volumes and manufacturing efficiencies are expected to reduce unit manufacturing costs. The Company says this would support significant improvements in gross margins over time.
Nigel Lange, CEO & Managing Director
“…This facility is a critical part of our strategy to build a scalable and capital-efficient manufacturing platform to support our growing global commercial activities. We expect it to significantly increase production capacity, strengthen supply chain resilience and deliver manufacturing efficiencies that have the potential to materially improve gross margins over time…”
What is a Notified Body and why does certification matter?
A Notified Body is an organisation that assesses whether a medical device and its manufacturing arrangements meet regulatory requirements for marketing in regulated markets. OncoSil Medical is seeking to have Macquarie Park included as a critical subcontractor under its existing certification.
That inclusion is the step the Company needs completed before commercial production at the site can begin, subject to the review and applicable approval processes.
The device already carries a substantial regulatory footprint. OncoSil™ has CE Marking approval, providing marketing authorisation in the European Union and the United Kingdom. It has also received US Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption for unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy.
OncoSil™ has been designated a Breakthrough Device in Europe and the United States, and is currently approved for sale in 30+ countries. The Company states that as it expands its international commercial activities, the ability to manufacture the device at significantly greater scale, efficiently and reliably, will be increasingly important.
The FDA approval granted in August 2026 opened the US market, with a full commercial launch targeted for the second half of FY27, which adds to the demand case that a scaled Australian manufacturing base is designed to serve.
What happens next for OncoSil Medical
The announcement sets out the following steps:
- Review by the Notified Body and completion of any associated regulatory requirements necessary to incorporate the Macquarie Park facility into the Company’s existing certification. No date is stated.
- Commencement of commercial production at Macquarie Park, targeted for 2H FY27, subject to the applicable regulatory review and approval processes.
- Further updates from the Company as material milestones are achieved.
The outcome of the Notified Body’s review is the key catalyst to watch, as it sits between the facility’s ISO 13485-certified quality system and the targeted start of commercial production.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to receive healthcare and medtech alerts the moment market-moving news breaks, so you stay ahead of the market.